Clinical characteristics, antihypertensive medication use and blood pressure control among patients with treatment-resistant hypertension: the Survey of PatIents with treatment ResIstant hyperTension study.
暂无分享,去创建一个
S. Oparil | E. Schiffrin | N. Poulter | J. Chalmers | B. Neal | K. Narkiewicz | K. Rogers | Ji G. Wang | M. Azizi | C. Carcel | J. G. Wang
[1] Corrigendum to: 2018 ESC/ESH Guidelines for the management of arterial hypertension. , 2018, European heart journal.
[2] David A Calhoun,et al. Resistant Hypertension: Detection, Evaluation, and Management: A Scientific Statement From the American Heart Association. , 2018, Hypertension.
[3] Thomas Kahan,et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension. , 2018, European heart journal.
[4] J. R. Nansseu,et al. Global prevalence of resistant hypertension: a meta-analysis of data from 3.2 million patients , 2018, Heart.
[5] D. Prabhakaran,et al. May Measurement Month 2017: an analysis of blood pressure screening results worldwide. , 2018, The Lancet. Global health.
[6] J. Williamson,et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. , 2018, Hypertension.
[7] W. Spiering,et al. Prevalence and clinical characteristics of apparent therapy-resistant hypertension in patients with cardiovascular disease: a cross-sectional cohort study in secondary care , 2017, BMJ Open.
[8] M. Fornage,et al. Heart Disease and Stroke Statistics—2017 Update: A Report From the American Heart Association , 2017, Circulation.
[9] M. Ng,et al. Prevalence, clinical characteristics and echocardiography parameters of non-resistant, resistant and refractory hypertension in Chinese , 2017, Postgraduate medicine.
[10] Steven M. Smith,et al. Trends in Antihypertensive Medication Use Among US Patients With Resistant Hypertension, 2008 to 2014 , 2016, Hypertension.
[11] K. Reynolds,et al. Global Disparities of Hypertension Prevalence and ControlClinical Perspective , 2016 .
[12] A. Høieggen,et al. Tertiary work-up of apparent treatment-resistant hypertension , 2016, Blood pressure.
[13] G. Bakris,et al. The double challenge of resistant hypertension and chronic kidney disease , 2015, The Lancet.
[14] S. Frey,et al. Systematic review and meta-analysis of the prevalence of resistant hypertension in treated hypertensive populations. , 2015, American journal of hypertension.
[15] A. Oliveras,et al. Resistant hypertension: do all definitions describe the same patients? , 2015, Journal of Human Hypertension.
[16] B. Davis,et al. Treatment-Resistant Hypertension and the Incidence of Cardiovascular Disease and End-Stage Renal DiseaseNovelty and Significance , 2014 .
[17] B. Davis,et al. Treatment-Resistant Hypertension and the Incidence of Cardiovascular Disease and End-Stage Renal Disease: Results From the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) , 2014, Hypertension.
[18] Alan S. Brown,et al. Proceedings from Duke resistant hypertension think tank. , 2014, American heart journal.
[19] J. Bisognano,et al. The prevalence, incidence, prognosis, and associated conditions of resistant hypertension. , 2014, Seminars in nephrology.
[20] S. Oparil,et al. Refractory Hypertension: Determination of Prevalence, Risk Factors, and Comorbidities in a Large, Population-Based Cohort , 2014, Hypertension.
[21] D. Calhoun,et al. Apparent and true resistant hypertension: definition, prevalence and outcomes , 2014, Journal of Human Hypertension.
[22] Philippe Van De Borne,et al. Guidelines for the management of arterial hypertension , 2014 .
[23] V. Pavlik,et al. Characteristics, drug combinations and dosages of primary care patients with uncontrolled ambulatory blood pressure and high medication adherence. , 2013, Journal of the American Society of Hypertension : JASH.
[24] H. Krum,et al. RAAS Inhibitors and Cardiovascular Protection in Large Scale Trials , 2013, Cardiovascular Drugs and Therapy.
[25] Heather M. Tavel,et al. Incidence and Prognosis of Resistant Hypertension in Hypertensive Patients , 2012, Circulation.
[26] J. Marrs,et al. Description of Antihypertensive Use in Patients With Resistant Hypertension Prescribed Four or More Agents , 2011, Hypertension.
[27] N. Poulter,et al. Baseline predictors of resistant hypertension in the Anglo-Scandinavian Cardiac Outcome Trial (ASCOT): a risk score to identify those at high-risk , 2011, Journal of hypertension.
[28] J. Banegas,et al. Clinical Features of 8295 Patients With Resistant Hypertension Classified on the Basis of Ambulatory Blood Pressure Monitoring , 2011, Hypertension.
[29] C. McAdam-Marx,et al. Results of a retrospective, observational pilot study using electronic medical records to assess the prevalence and characteristics of patients with resistant hypertension in an ambulatory care setting. , 2009, Clinical therapeutics.
[30] Daniel W. Jones,et al. Resistant hypertension: diagnosis, evaluation, and treatment: a scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. , 2008, Circulation.